No Data
Press Release: Poxel Reports Revenue for the Full Year 2024 and Provides an Update on Its Financial Position and Outlook
Japan paper, NRI, ETC (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Change After --------------------------------------------------------- <3861> Oji Holdings Nomura "Neutral" "Buy" Downgraded - Bearish Code Stock Name Brokerage Firm Previous Change After --------------------------------------------------------- <4477> BASE Daiwa "2" "3"
Rating Information (Target Price Change - Part 1) = Rengo, Gifty, ETC.
◎Nomura Securities (three-stage: Buy > neutral > Reduce) Rengo <3941.T> -- "Buy" to "Buy", 1370 yen to 1110 yen NRI <4307.T> -- "Buy" to "Buy", 5500 yen to 6000 yen KOKUSAI <6525.T> -- "Buy" to "Buy", 3700 yen to 3750 yen Panasonic <6752.T> -- "Buy" to "Buy", 2300 yen to 2500 yen Menicon <7780.T> -- "Buy" to "B
Foundation Medicine Collaborates With Sumitomo Pharma America to Advance Investigational Treatment for Patients With Acute Leukemia With NPM1 Mutations or KMT2A Rearrangements Using the FoundationOneHeme Platform
Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.
Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.
Fanpepp --- In the fiscal year ending December 2024, research and development will be advanced focusing on antibody-inducing peptide projects and functional peptides.
Fanpep Co., Ltd. <4881> announced its consolidated financial results for the fiscal year ending December 2024 on the 12th. Revenue was 0.006 billion yen (compared to 0 billion yen in the previous period), operating loss was 0.901 billion yen (compared to 0.994 billion yen in loss), ordinary loss was 0.896 billion yen (compared to 0.94 billion yen in loss), and net loss attributable to the Shareholder for the current period was 0.889 billion yen (compared to 0.933 billion yen in loss). In the antibody-inducing peptide project, the antibody-inducing peptide "FPP003" (target protein: IL-17A) is discussed.